Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05459493
Other study ID # TJ-IRB20220634-DOR
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date November 1, 2022
Est. completion date November 1, 2023

Study information

Verified date October 2022
Source Tongji Hospital
Contact Shixuan Wang, Professor
Phone +8613995553319
Email shixuanwang@tjh.tjmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently, no drugs have been developed for DOR. We developed the Chinese herbal compound TJAOA101 and has validated its effects in animals. Here, we will perform a population-based, multicenter study to confirm the safety and efficacy of TJAOA101 in therapy of DOR. We aim to provide a solid evidence for TCM in therapy of DOR.


Description:

As the pivotal reproductive organ, the ovaries have two main functions: ovulation and secretion of hormones. Ovarian dysfunction not only cause reproductive detriment, but also harms to each system and organ, arousing extensive concern of women. Diminished ovarian reserve (DOR) refers to the decline in ovarian function in advance with reduction of functional follicles and the ability to produce high quality oocytes, resulting in reduced fertility and the lack of sex hormones, leading to early menopause and infertility, and accelerated multiple organ aging including osteoporosis, cardiovascular disease, cognitive impairment. As DOR is an early stage of ovarian dysfunction, early intervention is necessary. Currently, several therapeutic approaches could be considered to prevent and attenuate unfavorable consequences of ovarian function decline. The hormone replacement therapy (HRT) can add exogenous sex hormones by replenishing the lack of hormones to relieve the symptoms caused by low level of estrogen, and then improve the health and life quality. HRT may can bring some benefits to women with DOR. However, it also has some limitations, for instance, it is mainly used for alleviating menopausal symptoms, while not to improve ovarian function. And there are some contraindications, such as breast cancer and blood clots, and HRT may increase the risk of abnormal uterine bleeding(AUB). In addition, dehydroepiandrosterone (DHEA), growth hormone(GH) and aspirin are considered the alternative treatments of DOR. However, due to the lack of large randomized controlled trials, the effectiveness of them needs further confirmation. Traditional Chinese medicine (TCM) has its own characteristic and superiority in treating diseases, with light side effects and remarkable curative effect. The Chinese nation accumulated a great deal of experience in TCM for treating ovarian dysfunction. Several studies showed that TCM is effective and safe in treating DOR. However, no guidelines for long-term TCM management in treating ovarian function decline exist at present. Clinical trials are imperative to test the safety and efficacy of these TCM prescriptions. And many prescriptions are complicated, mainly rely on the old experience with lacking sufficient scientific basis. To address this question, we have invented a brand new TCM prescription to treat DOR. Previously, we collected clinical TCM prescriptions from literature retrieval (CNKI and PubMed), and then created a database of recipes for treating ovarian function decline. By using Traditional Chinese Medicine Inheritance Support System (TCMISS) , key TCM and TCM combinations in DPTP were extracted to identify the candidate Chinese herbs. On this basis, gynostemma pentaphylla were added, efficacy and safety of which has been verified in drosophila and mice. Then, TJAOA101 (Tongji Anti-ovarian aging 101), a new TCM recipe was preliminarily developed by multiple experts of pharmacy and gynecology. And multiple model organisms including drosophila, mice of natural aging and chemotherapy damage were further used to verify the safety and effectiveness of TJAOA101 on ovarian function. Finally, the pharmacological action, dose, synergistic effect and incompatibility were determined. This study is a multicenter and prospective trial aiming to determine the safety and efficacy of TJAOA101 for preventing among women who were diagnosed with DOR. and aims to provide new strategies for improving ovarian reserve and function for DOR patients by evaluating the safety and efficacy of TJAOA1.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date November 1, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. The age range of patient is 18-40 years old. 2. Women with DOR, and wish to improve ovarian function or menopausal syndrome. The diagnostic criteria for DOR is as follows: If two of the following three tests of ovarian reserve function are met, DOR can be diagnosed: bilateral AFC<6; AMH < 1.1 ng/ml; 10 mIU/ml <bFSH<25 mIU/ml. 3. Sign the informed consent form. Exclusion Criteria: 1. Patient is known to be allergic or unsuitable for the Chinese herbal compound. 2. Women who are pregnant and lactating. 3. Patients had been menopause for more than 1 year. 4. Abnormal uterine bleeding, except ovulation disorders. 5. Women is taking hormone drugs and has stopped taking them within 3 months; 6. Women with endometriosis, myadenosis, submucosal fibroids or the size of non-submucosal fibroids is more than 4 cm. 7. The nature of pelvic mass is unknown. 8. Women with polycystic ovary syndrome, hyperprolactinemia, hyperandrogenemia, diabetes, thyroid and adrenal dysfunction and other endocrine diseases affecting ovulation. 9. Patients with serious primary diseases such as cardiovascular, liver, kidney, lung, biliary, hematopoietic system (Hb<90g/L) and malignant tumor, and psychiatric patients. 10. Patients are participating in other clinical trials or have participated in other clinical trials within the last month. 11. Unsuitable for the study evaluated by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TJAOA101
Once enrolled, participants will be administrated TJAOA101

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan

Sponsors (1)

Lead Sponsor Collaborator
Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary recovery rate of ovarian function As the definition of DOR is based on AMH or bFSH or AFC, the recovery of ovarian function is also based on the recovery of these indicators. In this study, the recovery of ovarian function is defined as serum AMH increased more than 50%, or serum bFSH decreased more than 50%, or antral follicle count(AFC) increased more than 50% compared with that before treatment,or recover to normal level. 6 months
Secondary recovery rate of menstruation two consecutive periods return to normal. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04972877 - Effect of Electro-acupuncture on Women With Diminished Ovarian Reserve N/A
Recruiting NCT04447872 - The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol N/A
Recruiting NCT05277948 - Effect of Thumbtack Needle on Ovarian Function of Women With Diminished Ovarian Reserve (DOR) N/A
Recruiting NCT04711772 - Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve
Recruiting NCT03670407 - Follicular Activation by Fragmentation of Ovarian Tissue N/A
Recruiting NCT06072794 - A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI) Phase 1
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Not yet recruiting NCT02099916 - Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF Phase 2/Phase 3
Not yet recruiting NCT06081257 - The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve N/A
Recruiting NCT06426355 - The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR N/A
Recruiting NCT04275700 - Study of PRP in Women With Evidence of Diminished Ovarian Reserve N/A
Recruiting NCT06223178 - Efficacy of Thumb-tack Needle Treatment for Diminished Ovarian Reserve N/A
Not yet recruiting NCT05577455 - Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients Phase 3
Recruiting NCT05665010 - Precise Stratification of Genetic Risk of Ovarian Function Impairment
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Terminated NCT01614067 - Delayed Start to Ovarian Stimulation Phase 4
Recruiting NCT06395623 - Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics
Recruiting NCT05847283 - DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT N/A
Recruiting NCT05485610 - Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency) N/A
Completed NCT04237909 - Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency N/A